Pfizer Inc. $PFE Shares Acquired by First Fiduciary Investment Counsel Inc.

Key Points

• First Fiduciary Investment Counsel Inc. increased its Pfizer position 18% in Q4 to 273,397 shares (added 41,665), worth about $6.81 million at quarter-end.
• Pfizer struck settlements that effectively extend U.S. exclusivity for its heart drug Vyndamax until roughly 2031, delaying generic competition and protecting medium‑term revenue.
• Pfizer declared a quarterly dividend of $0.43 (annualized $1.72) for a 6.5% yield

First Fiduciary Investment Counsel Inc. increased its position in Pfizer Inc. (NYSE:PFE - Free Report) by 18.0% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 273,397 shares of the biopharmaceutical company's stock after purchasing an additional 41,665 shares during the period. First Fiduciary Investment Counsel Inc.'s holdings in Pfizer were worth $6,808,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the company. Franklin Resources Inc. increased its holdings in shares of Pfizer by 47.8% in the 3rd quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company's stock valued at $638,787,000 after acquiring an additional 8,108,887 shares during the period. Vanguard Group Inc. boosted its stake in Pfizer by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company's stock worth $13,479,520,000 after purchasing an additional 7,031,162 shares during the period. Neuberger Berman Group LLC boosted its stake in Pfizer by 203.8% during the 3rd quarter. Neuberger Berman Group LLC now owns 9,012,811 shares of the biopharmaceutical company's stock worth $229,346,000 after purchasing an additional 6,045,763 shares during the period. Ameriprise Financial Inc. grew its position in Pfizer by 48.2% during the 3rd quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company's stock worth $468,174,000 after purchasing an additional 5,978,927 shares during the last quarter. Finally, AQR Capital Management LLC increased its stake in Pfizer by 120.9% in the third quarter. AQR Capital Management LLC now owns 9,505,615 shares of the biopharmaceutical company's stock valued at $230,986,000 after purchasing an additional 5,202,884 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Down 1.3%

Shares of NYSE:PFE opened at $26.45 on Wednesday. Pfizer Inc. has a fifty-two week low of $21.97 and a fifty-two week high of $28.75. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. The firm's 50-day simple moving average is $27.20 and its 200-day simple moving average is $26.09. The company has a market cap of $150.37 billion, a price-to-earnings ratio of 19.44 and a beta of 0.43.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm had revenue of $17.56 billion during the quarter, compared to analysts' expectations of $16.93 billion. During the same period in the prior year, the company posted $0.63 earnings per share. The firm's revenue for the quarter was down 1.2% on a year-over-year basis. As a group, equities research analysts predict that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.5%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer's dividend payout ratio (DPR) is currently 126.47%.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reached settlement agreements with three generic makers that effectively extend exclusivity on its heart drug, keeping generic rivals out of the U.S. market until about 2031 — a meaningful revenue-protection outcome for the product. Pfizer secures deals to keep heart drug free of generic rivals until 2031
• Positive Sentiment: Multiple outlets report the settlements specifically extend the effective U.S. patent life for Vyndamax (the branded heart drug), which should delay revenue erosion from generics and supports medium-term cash flow. Pfizer Stock Is Declining Today: What's Happening?
• Neutral Sentiment: Analyst and media pieces revisit Pfizer's dividend and income appeal (high yield), which supports longer‑term buy-and-hold interest even amid short-term volatility. Is Pfizer (PFE) One of the Best Fortune 500 Dividend Stocks to Invest in Right Now?
• Neutral Sentiment: Broader comparisons and strategy pieces (Novo Nordisk vs. Pfizer; buy/sell/hold guidance) highlight pipeline choices and longer-term growth questions — useful context but not immediate price drivers. Should You Buy, Sell, or Hold Pfizer at $27?
• Negative Sentiment: Zacks warns Q1 earnings are expected to decline and that Pfizer may lack the setup for an earnings beat this quarter — a near-term catalyst likely contributing to selling pressure. Earnings Preview: Pfizer (PFE) Q1 Earnings Expected to Decline
• Negative Sentiment: Market wrap and news roundups note Pfizer underperformed the broader market today — analysts attribute that to profit-taking, elevated volume of selling, and investor concern about near-term sales/earnings momentum despite the patent settlements. Why Pfizer (PFE) Dipped More Than Broader Market Today
• Negative Sentiment: Consumer-facing coverage flags the stock decline and summarizes investor uncertainty, reinforcing short-term negative sentiment and contributing to momentum-based selling. Pfizer stock is declining today: What's happening?

Wall Street Analysts Forecast Growth

PFE has been the subject of several recent research reports. TD Cowen reiterated a "hold" rating on shares of Pfizer in a research note on Tuesday, December 30th. HSBC boosted their price target on Pfizer from $29.00 to $32.00 and gave the company a "buy" rating in a research report on Tuesday, March 17th. Bank of America decreased their price objective on Pfizer from $27.00 to $26.00 and set a "neutral" rating for the company in a research report on Thursday, April 9th. UBS Group lifted their target price on Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a research note on Monday, April 13th. Finally, Daiwa Securities Group lowered Pfizer from an "outperform" rating to a "neutral" rating and set a $27.00 target price on the stock. in a report on Thursday, February 12th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, fourteen have given a Hold rating and three have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $28.48.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.